Hazard characterisation of chemicals in food and diet: Dose response, mechanisms and extrapolation issues

Food and Chemical Toxicology

Volumn 40, Issue 2-3, 2002, Pages 237-282

  Dybing, E ^a   Doe, J ^b   Groten, J ^c   Kleiner, J ^d   O'Brien, J ^e   Renwick, A G ^f   Schlatter, J ^g   Steinberg, P ^h   Tritscher, A ⁱ   Walker, R ^j   Younes, M ^k  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b JEALOTT S HILL INTERNATIONAL RESEARCH CENTRE   (United Kingdom)

^c TNO   (Netherlands)

^d International Life Sciences Institute of Europe   (Belgium)

^e DANONE RESEARCH   (France)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^g FEDERAL OFFICE OF PUBLIC HEALTH   (Switzerland)

^h UNIVERSITY OF POTSDAM   (Germany)

ⁱ NESTLÉ RESEARCH CENTER   (Switzerland)

^j UNIVERSITY OF SURREY   (United Kingdom)

^k WORLD HEALTH ORGANIZATION   (Switzerland)

more..

Author keywords

Chemicals; Hazard characterisation; Macronutrients; Micronutrients; Mixtures

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ACETYLSALICYLIC ACID; CARCINOGEN; CLOFIBRATE; FERTILIZER; FOOD ADDITIVE; ORAL CONTRACEPTIVE AGENT; PENICILLIN G; PESTICIDE; PHENOBARBITAL; SACCHARIN; TRACE ELEMENT;

ARTICLE; BIOAVAILABILITY; BIOTRANSFORMATION; CARCINOGENICITY; CELL ENERGY; CYTOTOXICITY; DIET; DNA REPAIR; EXPERIMENTAL MODEL; FOOD INTAKE; FOOD SAFETY; GASTROINTESTINAL ABSORPTION; HAZARD ASSESSMENT; HEALTH STATUS; HOMEOSTASIS; HORMESIS; HUMAN; MACRONUTRIENT; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; QUALITY CONTROL; RECEPTOR BINDING; RISK ASSESSMENT; SPECIES DIFFERENCE; TOXICOKINETICS; URINARY EXCRETION;

ANIMALIA; RODENTIA;

EID: 0036122484     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-6915(01)00115-6     Document Type: Review

References (229)

1. Concluding remarks on the proposed safety appraisal framework for evaluating macronutrient substitutes
2. Glutathione-dependent toxicity
3. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride
4. Safety evaluation of phytosterol esters. Part 1. Assessment of oestrogenicity using a combination of in vivo and in vitro assays
5. Subchronic oral toxicity study with regular and enzymatically depolymerized sodium carboxymethylcellulose in rats
6. Hazard identification by methods of animal-based toxicology
7. Biochemical pathways in cadmium toxicity
8. The toxicity of poisons applied jointly
9. 2u-globulin nephropathy
10. The safety evaluation of macronutrient substitutes
11. Post-marketing surveillance of macronutrient substitutes
12. A proposed model for safety assessment of macronutrient substitutes
13. Biochemical mechanisms in chemical-induced lung injury: Roles of metabolic activation
14. Possible mechanism of liver necrosis caused by aromatic compounds
15. Does the animal-to-human uncertainty factor incorporate differences in surface area?
16. Can the concept of hormesis be generalized to carcinogenesis?
17. Comparative aspects of detoxication in mammals
18. The current status of attempts to predict species differences in lung metabolism
19. The role of N-acetyltransferse phenotypes in bladder carcinogenesis: A pharmacogenetic epidemiological approach to bladder cancer
20. Changes in the nasal epithelium of rats exposed by inhalation to mixtures of formaldehyde, acetaldehyde and acrolein
21. Sensory irritation to mixtures of formaldehyde, acrolein, and acetaldehyde in rats
22. Toxicological evaluation and risk assessment of chemical mixtures
23. Rodent bladder tumors do not always predict for humans
24. Role of urinary physiology and chemistry in bladder carcinogenesis
25. Calcium phosphate-containing urinary precipitate in rat urinary bladder carcinogenesis
26. Basic principles of target organ toxicity
27. Regulation of drug metabolism of drug metabolism in man by environmental chemicals and diet
28. The role of the nucleus and other compartments in toxic cell death produced by alkylating hepatotoxicants
29. The dose-dependent effect of BHT (butylated hydroxytoluene) on vitamin K-dependent blood coagulation in rats
30. Principles underlying dose selection for, and extrapolation from, the carcinogen bioassay: Dose influences mechanism
31. Fundamental carcinogenic processes and their implications for low dose risk assessment
32. Phthalate migration from soft PVC toys and child-care articles
33. Nasal cavity enzymes involved in xenobiotic metabolism: Effects on the toxicity of inhalants
34. Metabolic polymorphisms
35. Toxicity of vitamins
36. Biological basis for extrapolation across mammalian species
37. Bioactivation of nephrotoxins and renal carcinogens by glutathione S-conjugate formation
38. Regulatory history and experimental support of uncertainty (safety) factors
39. Evolution of science-based uncertainty factors in noncancer risk assessment
40. Nutrition, cancer, and aging
41. Quantitative aspects of chemical carcinogenesis
42. Mutagenicity and organ damage of DBCP and Tris-BP: Role of metabolic activation
43. Situations with enhanced chemical risks due to toxicokinetic and toxicodynamic factors
44. Lack of carcinogenic activity and metabolic fate of fluorenylacetamides in monkeys
45. Mechanisms of aflatoxin carcinogenesis
46. Mathematical modeling and quantitative methods
47. Proceedings of a workshop "Assessing health risks from environmental exposure to chemicals: The example of drinking water", 18-20 May, 1998
48. Methods of in vitro toxicology
49. Receptors for γ-aminobutyric acid and voltage-dependendt chloride channels as targets for drugs and toxicants
50. The health risks of saccharin revisited
51. Effects of glutathione transferase theta polymorphism on the risk estimates of dichloromethane to humans
52. Summary of the symposium establishing the safety of fat and macronutrients substitutes presented at the 33rd annual meeting of the Society of Toxicology, San Diego, California, March 13-17, 1994
53. The human relevance of the renal tumor-inducing potential of d-limonene in male rats: Implications for risk assessment
54. Increased dietary cadmium absorption in mice and human subjects with iron deficiency
55. The need for human data: The role of clinical trials and postmarketing surveillance in the safety assessment of macronutrient substitutes
56. P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulcation of drugs
57. Transfer of persistent chemicals in milk
58. Relative potency of chemical carcinogens in rodents
59. Economical designs for detecting and characterizing departure from additivity in mixtures of many chemicals
60. Disposition of polycyclic aromatic hydrocarbons in the respiratory tract of the beagle dog. I. The alveolar region
61. Physiologically based pharmacokinetic modeling: Principles and applications
62. Hepatotoxicology of copper, iron and cadmium
63. Interspecies extrapolation in carcinogenesis: Prediction between rats and mice
64. A carcinogenic potency database of the standardized results of animal bioassays
65. The role of glutathione conjugation in the development of kidney tumours in rats exposed to trichloroethylene
66. An analysis of the possibility for health implications of joint actions and interactions between food additives
67. Sub-acute toxicity of a combination of nine chemicals in rats: Detecting interactive effects with a two level factorial design
68. Sex steroid induced changes in hepatic enzymes
69. Apoptosis in colorectal tumour cells: Induction by the short chain fatty acids butyrate, propionate and acetate and by the bile salt deoxycholate
70. The short-chain fatty acid butyrate induces apoptosis in colorectal tumour cell lines
71. Acetylation phenotype and bladder cancer
72. 2u-globulin, hyaline droplet nephropathy, and tubule neoplasia in the kidneys of male rats
73. Disturbance of DNA damage recognition after UV-irradiation by nickel (II) and cadmium (II) in mammalian cells
74. Carcinogenicity of metal compounds: Possible role of DNA repair inhibition
75. Interaction of arsenic(III) with nucleotide excision repair in UV-irradiated human fibroblasts
76. Safety limits for nutrient intakes: Concepts and data requirements
77. Transport of essential nutrients across the blood-brain barrier of individual structures
78. N-Acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers
79. Experimental designs and risk assessment in combination toxicology: Panel discussion
80. Safety evaluation of phytosterol esters. Part 2. Subchronic 90-day oral toxicity study on phytosterol esters - A novel functional food
81. Aflatoxin induced lesions in Syrian hamsters
82. The role of metabolic activatioin in drug toxicity
83. Hypnotics and sedatives; ethanol
84. Nonlinearity of dose-response functions for carcinogenicity
85. Drug metabolism in liver disease
86. Stimulation of apoptosis by two prebiotic chicory fructans in the rat colon
87. Acetylation phenotype in colorectal carcinoma
88. Interspecies scaling and comparisons in drug development and toxicokinetics
89. Enzymes involved in cyanide metabolism
90. The safety assessment of novel foods
91. The additivity assumption tested for combinations of similarly acting nephrotoxicants
92. Evaluation of the use of uncertainty factors in deriving RfDs for some chlorinated compounds
93. Roles for insulin-like growth factor-1 in mediating the anti-carcinogenic effects of caloric restriction
94. Cobalt(II) inhibits the incision and the polymerization step of nucleotide excision repair in human fibroblasts
95. The effects of diet, overfeeding and moderate dietary restriction on Sprague-Dawley rat survival, disease and toxicology
96. Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiol-3-thiones and 1,2-dithiol-3-ones
97. Chemoprotection by organosulfur inducers of phase 2 enzymes: Dithiolethiones and dithiins
98. The effect of pregnancy on the pharmacokinetics of caffeine
99. First-pass metabolism of cyclosporin by the gut
100. Mitochondrial effects of triarylmethane dyes
101. Extrapolation of experimental data from animals to man
102. On the mechanisms of action of carcinogenic aromatic amines. I. Binding of 2-acetylaminofluorene and N-hydroxy-2-acetylaminofluorene to rat liver nucleic acids in vivo
103. Threshold of toxicological concern for chemical substances present in the diet: A practical tool for assessing the need for toxicity testing
104. Effects of inulin on faecal bifidobacteria in human subjects
105. Disposition of ivermecting and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein
106. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure for food-borne heterocyclic amines increase the risk for colorectal cancer or polyps
107. Role of aromatic amine acetyltransferase in human colorectal cancer
108. α2u-Globulin nephropathy
109. Seasonality, body size and survival time in mammals
110. Body size, physiological time, and longevity of homeothermic animals
111. Effects of caloric restriction or augmentation in adult rats: Longevity and lesion markers of aging
112. Effects of dose and time in a long-term, low-dose carcinogenesis study
113. N-acetyltransferase phenotype and risk in urinary bladder cancer: Approaches in molecular epidemiology. Preliminary results in Sweden and Denmark
114. Safety assessments of chemicals with threshold effects
115. Acceptable daily intake: Inception, evolution, and application
116. Low digestible carbohydrates (polyols and lactose): Significance of adrenal medullary proliferative lesions in the rat
117. Mechanistic considerations for the relevance of animal data on thyroid neoplasia to human risk assessment
118. Concepts in health evaluation of commercial and industrial chemicals
119. Epithelia: Biologic principles of organization
120. 1 metabolism
121. Toxicology of pesticides
122. Risk assessment of essential trace elements: New approaches to setting recommended daily allowances and safety limits
123. The comparative carcinogenicities of 2-acetylaminofluorene and its N-hydroxy metabolite in mice, hamsters, and guinea pigs
124. Carcinogenesis by chemicals: An overview - G.H.A. Clowes memorial lecture
125. Some historical perspectives on the metabolism of xenobiotic chemicals to reactive electrophiles
126. The paradoxical lack of interspecies correlation between plasma concentrations and chemical carcinogenicity
127. Pharmacokinetic scale-up: Accurate prediction of human pharmacokinetic profiles from animal data
128. Man versus beast: Pharmacokinetic scaling in animals
129. Scientific evaluation of data-derived safety factors for the acceptable daily intake. Case study: Diethylhexylphthalate
130. A weight of evidence approach for assessing interactions in chemical mixtures
131. Evaluation of chemical mixtures of public health concern: Estimation vs. experimental determination of toxicity
132. Alternative approaches to the safety assessment of macronutrient substitutes
133. Toxic effects of pesticides
134. Selected issues in risk assessment. II
135. Subchronic to chronic exposure extrapolation: Toxicologic evidence for a reduced uncertainty factor
136. Toxicokinetics: Distribution of toxicants. Comprehensive toxicology
137. Molecular biology of the aromatic hydrocarbon (dioxin) receptor
138. The rat as a model for human toxicological evaluation
139. Metabolic activation in drug allergies
140. Evaluation of the uncertainty factor for subchronic-to-chronic extrapolation: Statistical analysis of toxcity data
141. Physicochemical differences in the Ah receptors of the most TCDD-susceptible and the most TCDD-resistant rat strains
142. 2,3,7,8-Tectrachlorodibenzo-p-dioxin and related aromatic hydrocarbons: Examination of the mechanism of toxicity
143. Lactobacillus- and Bifidobacterium-mediated antigenotoxicity in colon cells of rats: Prevention of carcinogen-induced damage in vivo and elucidation of involved mechanisms
144. Case study: Erythrosine
145. Thresholds in chemical carcinogenesis
146. Species, strain and sex differences in metabolism of hexobarbitone, amidopyrine, antipyrine and aniline
147. The primary aromatic amines: Their biological properties and structure-activity relationships
148. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility - A review
149. Safety factors and establishment of acceptable daily intakes
150. Toxicokinetcs
151. Data-derived safety factors for the evaluation of food additives and environmental contaminants
152. Exposure estimation, toxicological requirements and risk assessment
153. Human variability and noncancer risk assessment - An analysis of the default uncertainty factor
154. Toxicokinetics: Routes of elimination
155. Tetrodotoxin and saxitoxin and the sodium channels of excitable tissues
156. Perspectives in carbohydrate toxicology with special reference to carcinogenicity
157. Enzootic and epizootic adrenal medullary proliferative disease of rats: Influence of dietary factors which affect calcium absorption
158. The Leon Golberg Memorial Lecture. Recent advances in toxicology relevant to carcinogenesis: Seven cameos
159. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma
160. Nutrition and gut flora metabolism
161. Effect of Bifidobacterium longum and inulin on gut bacterial metabolism and carcinogen-induced aberrant crypt foci in rats
162. FDA's priority based assessment of food additives
163. Acetaminophen poisoning and toxicity
164. Comparative toxicology and mechanism of action of polychlorinated diben-p-dioxins and dibenzofurans
165. Environmental and dietary estrogens and human health: Is there a problem?
166. Physiological and patho-physiological alterations in rat hepatic cytochrome P-450
167. An integrated in vivo and in vitro strategy to improve food safety evaluation
168. Statistical designs in combination toxicology: A matter of choice
169. Oxidative stress: Oxidants and antioxidants
170. Bifidobacterium longum, a lactic acid-producing intestinal microflor, inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis
171. Thresholds in toxicology and risk assessment
172. A probailistic approach for deriving acceptable human intake limits and human health risks from toxicological studies: General framework
173. Bioassaydesign and MTD setting: Old methods and new approaches
174. Statistically designed experiments in a tiered approach to screen mixtures of Fusarium mycotoxins for possible interactions
175. Antithyroid effects of propylthiouracil and sulfamonomethoxine in rats and monkeys
176. Review article: Olestra and its gastrointestinal safety
177. Tumor incidence in a chemical carcinogenesis study of nonhuman primates
178. Disposition of butadiene monoepoxide and butadiene diepoxide in various tissues of rats and mice following a low-level inhalation exposure to 1,3-butadiene
179. Oral first-pass elimination of midazolam invovles both gastrointestinal and hepatic CYP3A-mediated metabolism
180. The concept of acceptable daily intake: An historical review
181. Calcium-mediated cell injury and cell death
182. Toxic equivalency factors (TEFs) for PCBs, PCDDs, PCDFs for humans and wildlife
183. The contribution of epidemiology
184. Assessment factors for human health risk assessment: A discussion paper
185. Dietary inulin improves distal colitis induced by dextran sodium sulfate in rats
186. The effect of stress on toxicological investigations
187. Species differences in microsomal monooxygenase activity and the relationship of biological half-livers
188. Toxicokinetics: Oral exposure and absorption of toxicants
189. Receptor and nonreceptor-mediated organ-specific toxicity of di(2-ethylhexyl)phathalate (DEHP) in peroxisome proliferator-activated receptor alpha-null mice
190. The metabolic barrier of the gastrointestina tract
191. Relationshp between short-term and long-term feeding studies indesigning an effective toxicity test
192. Consultation on assessment of the health risk of dioxins; re-evaluation of the tolerable daily intake (TDI): Executive summary
193. Arsenic
194. Aflatoxin carcinogenesis
195. Aromatic amine acetyltransferase as a marker for colorectal cancer: Environmental and demographic associations
196. The human hepatic cytochromes P450 involved in drug metabolism
197. Risk assessment and management
198. Phytic acid in health and disease